Exhibit 1.01

Conflict Minerals Report

Introduction

Keenova Therapeutics plc, formerly Mallinckrodt plc, is a global business consisting of multiple wholly owned subsidiaries (collectively, “Keenova” or “the Company”) that develop, manufacture and commercialize a portfolio of branded therapeutics for the treatment of rare or unaddressed diseases in the specialty areas of rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.

This Conflict Minerals Report (“CMR”) for the reporting period of January 1 through December 31, 2025 (“the Reporting Period”) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (“the Rule”). The Rule imposes certain reporting obligations on U.S. Securities and Exchange Commission (“SEC”) issuers whose manufactured products contain certain minerals which are necessary to the functionality or production of their products. These minerals are cassiterite, columbite-tantalite (coltan), gold, wolframite, and their derivatives, which are limited to tin, tantalum and tungsten (“3TG(s)” or “Conflict Minerals”). The Rule focuses on 3TG emanating from the Democratic Republic of the Congo (“DRC”) region and nine adjoining countries (together, the “Covered Countries”). If an issuer has reason to believe that any of the Conflict Minerals in their supply chain may have originated in the Covered Countries, or if they are unable to determine the country of origin of those Conflict Minerals, then the issuer must exercise due diligence on the Conflict Minerals’ source and chain of custody and submit a CMR to the SEC that includes a description of those due diligence measures.

This CMR relates to the process undertaken for Keenova products that were manufactured, or contracted to be manufactured, during the Reporting Period and that contain Conflict Minerals. The Company's policy with respect to the sourcing of conflict minerals (the “Conflict Minerals Policy”) can be found on its website at https://www.keenova.com/company/policies/.

Executive Summary

Keenova performed a Reasonable Country of Origin Inquiry (“RCOI”) on suppliers believed to provide Keenova with materials or components containing 3TGs necessary to the manufacture of Keenova’s medical device products. Keenova’s suppliers listed 334 valid smelters and refineries (“smelters”) as possible sources for 3TGs in their components. Of the 334 listed smelters, Keenova identified 48 that may be sourcing from the Covered Countries. Keenova’s due diligence review indicated that 32 of these smelters have been audited and are conformant to the Responsible Minerals Assurance Process (“RMAP”). The remaining 16 smelters were subject to Keenova’s risk mitigation process consistent with the Organisation for Economic Co-operation and Development (“OECD”) Due Diligence Guidance for Responsible Supply Chain of Minerals from Conflict-Affected and High-Risk Areas (“OECD Due Diligence Guidance”).

Company Management Systems

Keenova’s strong management systems were established consistent with Step 1 of the OECD Due Diligence Guidance. Keenova’s management systems include:

Reasonable Country of Origin Inquiry (RCOI)

Keenova designed its RCOI process in accordance with Step 2A and 2B of the OECD Due Diligence Guidance. Keenova’s RCOI process involved two stages:

Supplier RCOI

Keenova designed its supplier RCOI process to identify, to the best of its efforts, the smelters in Keenova’s supply chain in accordance with Step 2A of the OECD Due Diligence Guidance. Keenova’s supplier RCOI process for the Reporting Period included the following:

For the Reporting Period, Keenova’s RCOI process was executed by Claigan Environmental Inc. (“Claigan”).

Keenova’s suppliers identified 334 smelters in their supply chain. The specific list of smelters is included in the Smelter and Refineries section at the end of this CMR.

Smelter RCOI

Due to the overlap between smelter RCOI and smelter due diligence, the smelter RCOI process is summarized in the Due Diligence section of this CMR.

Due Diligence

Keenova’s “Due Diligence Process” was designed in accordance with the applicable sections of Steps 2, 3, and 4 of the OECD Due Diligence Guidance.

Smelter RCOI and Due Diligence

Keenova’s smelter RCOI and Due Diligence Process were designed to:

Keenova’s smelter RCOI and Due Diligence Process included the following:

For the Reporting Period, Keenova’s smelter RCOI and Due Diligence Process was executed by Claigan.

Keenova’s suppliers identified 334 smelters. Keenova identified 48 smelters that source, or there is reason to believe they may source, from the Covered Countries.

Keenova determined that 32 of these 48 smelters have been audited and are conformant to the RMAP, as of May 14, 2025.

Risk Mitigation

Keenova continues to be committed to conducting risk mitigation on the remaining 16 high-risk smelters that may be part of the supply chain. Keenova’s risk mitigation was designed in accordance with Step 3B of the OECD Due Diligence Guidance and was reported to designated senior management consistent with the principles of Step 3A of the OECD Due Diligence Guidance. Keenova’s risk mitigation process included the following:

Keenova found that one of the high-risk smelters had ceased smelting operations and transferred production to another facility which is RMAP Conformant.

Improvement Plan

Keenova strives to improve the due diligence conducted to further mitigate risk that the necessary Conflict Minerals in Keenova’s products could directly or indirectly benefit or finance armed groups in the Covered Countries and will aim to take the following steps:

Website addresses are included in this CMR for reference only. Any information contained on Keenova’s website is not incorporated by reference into this CMR.

Smelters and Refiners

Below are the smelters reported to Keenova as possibly in the Company’s supply chain in the Reporting Period.